Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice

Not yet recruitingOBSERVATIONAL

Enrollment

240

Participants

Timeline

Start Date

July 31, 2025

Primary Completion Date

July 1, 2029

Study Completion Date

July 1, 2029

Conditions

Breast Cancer

Interventions

DRUG

Ribociclib

CDK4/6 inhibitor

DRUG

Letrozole

Aromatase inhibitor

DRUG

Anastrozole

Aromatase inhibitor